NeuroSense Payables Turnover from 2010 to 2024

NRSNW Stock  USD 0.25  0.01  4.17%   
NeuroSense Therapeutics Payables Turnover yearly trend continues to be fairly stable with very little volatility. Payables Turnover is likely to outpace its year average in 2024. Payables Turnover is a liquidity ratio that shows how quickly NeuroSense Therapeutics Ltd pays off its suppliers by dividing total purchases by average accounts payable. View All Fundamentals
 
Payables Turnover  
First Reported
2010-12-31
Previous Quarter
0.06648389
Current Value
0.0754
Quarterly Volatility
0.03201791
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 101.8 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Check out the analysis of NeuroSense Therapeutics Correlation against competitors.
For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

Latest NeuroSense Therapeutics' Payables Turnover Growth Pattern

Below is the plot of the Payables Turnover of NeuroSense Therapeutics Ltd over the last few years. It is a liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable. NeuroSense Therapeutics' Payables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Payables Turnover10 Years Trend
Slightly volatile
   Payables Turnover   
       Timeline  

NeuroSense Payables Turnover Regression Statistics

Arithmetic Mean0.07
Geometric Mean0.06
Coefficient Of Variation48.15
Mean Deviation0.02
Median0.05
Standard Deviation0.03
Sample Variance0
Range0.1242
R-Value0.46
Mean Square Error0.0009
R-Squared0.21
Significance0.08
Slope0
Total Sum of Squares0.01

NeuroSense Payables Turnover History

2024 0.0754
2023 0.0665
2022 0.18
2021 0.0769

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Payables Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Payables Turnover 0.07  0.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.